About
Contact & Profiles
A5089907367
Research Areas
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Neuropeptides and Animal Physiology
- Diabetes Treatment and Management
Queen's University Belfast
2016
Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor activation, the metabolically-inactive breakdown product, GLP-1(9-36)amide, also appears exert notable effects, including protection against acute cardiac ischaemia. Here, we specifically studied influence of GLP-1(9-36)amide on chronic post-myocardial infarction (MI) remodelling, which...
10.1186/s12933-016-0386-5
article
EN
cc-by
Cardiovascular Diabetology
2016-04-14
Coming Soon ...